摘要
背景：磷酸二酯酶5抑制剂(PDE5I)是治疗盆腔肿瘤术后勃起功能障碍(ED)的一线药物。我们研究的目的是评估PDE5Is的有效性的现有证据，包括新的配方和骨盆手术后的阴茎康复。 取证：对这些文献进行了系统的回顾，直到2020年5月。检索了以下数据库:Scopus, Medline和Web of Science。网状搜索结合以下术语进行:“勃起功能障碍”、“根治性前列腺切除术”、“骨盆”、“膀胱”、“磷酸二酯酶抑制剂”、“阿伐那非”、“西地那非”、“他达拉非”、“洛地那非”、“米地那非”、“伊地那非”、“伐地那非”、“舌下的”、“口分散的”、“阴茎”、“康复”。 证据分析：与安慰剂相比，西地那非、他达拉非、伐地那非和阿伐那非改善了根治性前列腺切除术后所有级别ED严重程度男性患者的EF，且耐受性良好。对于一种药物优于另一种药物，不能提出具体的建议。最佳剂量，持续与按需和治疗持续时间，仍在调查中。体外和临床前研究表明，洛地那非、米罗地那非和奥罗分散制剂可能在接受肿瘤盆腔手术的患者中发挥作用。很少有研究表明伊地那非在改善直肠手术或根治性前列腺切除术后ED的疗效。在骨盆手术后阴茎康复领域中，手术后EF的完全恢复仍然是一个未被满足的需求。 结论：PDE5Is在ED盆腔手术后的治疗中起着至关重要的作用。新药和新配方在ED患者中取得了良好的疗效;然而，关于术后患者的资料仍然缺乏。进一步的精心设计的随机对照试验应该阐明这些新的化合物和口分散性配方在盆腔手术患者的ED治疗中的作用。
关键词: 磷酸二酯酶5抑制剂，手术，盆腔，勃起功能障碍，根治性前列腺切除术，阴茎康复，口分散的。
图形摘要
[1]
Salonia A, Adaikan G, Buvat J, Carrier S, El-Meliegy A, Hatzimouratidis , et al. Sexual rehabilitation after treatment for prostate cancer—part 1: Recommendations from the fourth international consultation for sexual medicine (ICSM 2015). J Sex Med 2017; 14: 285-96.
[2]
Foo KT. From evidence-based medicine to evidence-balanced medicine for individualized and personalized care: As applied to benign prostatic hyperplasia/male lower urinary tract symptoms. Int J Urol 2017; 24: 94-5. http://www.ncbi.nlm.nih.gov/pubmed/ 28191718
[3]
De Nunzio C, Pastore AL, Lombardo R, Cancrini F, Carbone A, Fuschi A, et al. The EORTC quality of life questionnaire predicts early and long-term incontinence in patients treated with robotic assisted radical prostatectomy: Analysis of a large single center cohort. Urol Oncol Semin Orig Investig 2019; 37: 1006-3.http://www.ncbi.nlm.nih.gov/pubmed/31326315
[4]
Capogrosso P, Vertosick EA, Benfante NE, et al. Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade. Eur Urol 2019; 75(2): 221-8.
[http://dx.doi.org/10.1016/j.eururo.2018.08.039] [PMID: 30237021]
[http://dx.doi.org/10.1016/j.eururo.2018.08.039] [PMID: 30237021]
[5]
Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, Graefen M, et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 2012; 418-30.http://www.ncbi.nlm.nih.gov/pubmed/22749850
[6]
Montorsi F, Guazzoni G, Strambi LF, Da Pozzo LF, Nava L, Barbier L, et al. Recovery of spontaneous erectile function after nervesparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: Results of a prospective, randomized trial. J Urol Elsevier Inc 1997; 158: 1408-10.
[7]
Mulhall JP, Land S, Parker M, Waters WB, Flanigan RC, Burnett AL, et al. The use of an erectogenic pharmacotheraphy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med 2005; 2: 532-40.http://www.ncbi.nlm.nih.gov/pubmed/16422848
[8]
Salonia A, Adaikan G, Buvat J, Carrier S, El-Meliegy A, Hatzimouratidis K, et al. Sexual Rehabilitation After Treatment For Prostate Cancer—Part 2: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med 2017; 14: 297-315.
[9]
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49(6): 822-30.
[http://dx.doi.org/10.1016/S0090-4295(97)00238-0] [PMID: 9187685]
[http://dx.doi.org/10.1016/S0090-4295(97)00238-0] [PMID: 9187685]
[10]
Laumann EO, Paik A, Rosen RC. Sexual Dysfunction in the United States: Prevalence and Predictors. JAMA J Am Med Assoc 1999; 281: 537-44.http://www.ncbi.nlm.nih.gov/pubmed/17365514
[11]
Peng Z, Yang L, Dong Q, Wei Q, Liu L, Yang B. Efficacy and safety of tadalafil once-a-day versus tadalafil on-demand in patients with erectile dysfunction: A systematic review and meta-analyses. Urol Int 2017; 99: 343-52.https://www.karger.com/Article/FullText/477496
[http://dx.doi.org/10.1159/000477496]
[http://dx.doi.org/10.1159/000477496]
[12]
Montorsi F, Brock G, Stolzenburg JU, et al. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT). Eur Urol 2014; 65(3): 587-96.
[http://dx.doi.org/10.1016/j.eururo.2013.09.051] [PMID: 24169081]
[http://dx.doi.org/10.1016/j.eururo.2013.09.051] [PMID: 24169081]
[13]
Montorsi F, Oelke M, Henneges C, Brock G, Salonia A, d’Anzeo G, et al. Exploratory Decision-Tree Modeling of Data from the Randomized REACTT Trial of Tadalafil Versus Placebo to Predict Recovery of Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy. Eur Urol 2016; 70: 529-37. http://www.ncbi.nlm.nih.gov/ pubmed/26947602
[http://dx.doi.org/10.1016/j.eururo.2016.02.036]
[http://dx.doi.org/10.1016/j.eururo.2016.02.036]
[14]
Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol 2004; 171: 771-4. http://www.ncbi.nlm.nih.gov/pubmed/ 14713808
[15]
Padma-Nathan H, McCullough AR, Levine LA, et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008; 20(5): 479-86.
[http://dx.doi.org/10.1038/ijir.2008.33] [PMID: 18650827]
[http://dx.doi.org/10.1038/ijir.2008.33] [PMID: 18650827]
[16]
Pavlovich CP, Levinson AW, Su LM, et al. Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo. BJU Int 2013; 112(6): 844-51.
[http://dx.doi.org/10.1111/bju.12253] [PMID: 23937708]
[http://dx.doi.org/10.1111/bju.12253] [PMID: 23937708]
[17]
Kim DJ, Hawksworth DJ, Hurwitz LM, et al. A prospective, randomized, placebo-controlled trial of on-Demand vs. nightly sildenafil citrate as assessed by Rigiscan and the international index of erectile function. Andrology 2016; 4(1): 27-32.
[http://dx.doi.org/10.1111/andr.12118] [PMID: 26663669]
[http://dx.doi.org/10.1111/andr.12118] [PMID: 26663669]
[18]
Montorsi F, Brock G, Lee J, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008; 54(4): 924-31.
[http://dx.doi.org/10.1016/j.eururo.2008.06.083] [PMID: 18640769]
[http://dx.doi.org/10.1016/j.eururo.2008.06.083] [PMID: 18640769]
[19]
Li J, Peng L, Cao D, He L, Li Y, Wei Q. Avanafil for the Treatment of men With Erectile Dysfunction: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Am J Mens Health 2019; 13.
[20]
Mulhall JP, Burnett AL, Wang R, McVary KT, Moul JW, Bowden CH, et al. A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. J Urol 2013; 189: 2229-36.http://www.ncbi.nlm.nih.gov/pubmed/23219537
[21]
Sperling H, Gittelman M, Norenberg C, Ulbrich E, Ewald S. Efficacy and Safety of an Orodispersible Vardenafil Formulation for the Treatment of Erectile Dysfunction in Elderly Men and Those with Underlying Conditions: An Integrated Analysis of Two Pivotal Trials. J Sex Med 2011; 8: 261-71. http://www.ncbi.nlm.nih. gov/pubmed/20807322
[22]
Scaglione F, Donde S, Hassan TA, Jannini EA. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction: Pharmacology and clinical impact of the sildenafil citrate orodispersible tablet formulation. Clin Ther Excerpta Medica Inc 2017; 370-7.http://www.ncbi.nlm.nih.gov/pubmed/28139291
[23]
Cocci A, Cito G, Urzì D, et al. Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie’s Disease: A Matched-Pair Comparison Analysis. J Sex Med 2018; 15(10): 1472-7.
[http://dx.doi.org/10.1016/j.jsxm.2018.08.012] [PMID: 30245025]
[http://dx.doi.org/10.1016/j.jsxm.2018.08.012] [PMID: 30245025]
[24]
Ding H, Du W, Wang H, et al. Efficacy and safety of udenafil for erectile dysfunction: a meta-analysis of randomized controlled trials. Urology 2012; 80(1): 134-9.
[http://dx.doi.org/10.1016/j.urology.2012.02.014] [PMID: 22497982]
[http://dx.doi.org/10.1016/j.urology.2012.02.014] [PMID: 22497982]
[25]
Kim TH, Ha YS, Choi SH, et al. Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy. Int J Impot Res 2016; 28(1): 25-30.
[http://dx.doi.org/10.1038/ijir.2015.28] [PMID: 26510966]
[http://dx.doi.org/10.1038/ijir.2015.28] [PMID: 26510966]
[26]
Park SY, Choi GS, Park JS, Kim HJ, Park JA, Choi JI. Efficacy and safety of udenafil for the treatment of erectile dysfunction after total mesorectal excision of rectal cancer: A randomized, double-blind, placebo-controlled trial. Surg (United States) 2015; 157: 64-71.
[http://dx.doi.org/10.1016/j.surg.2014.07.007]
[http://dx.doi.org/10.1016/j.surg.2014.07.007]
[27]
Toque HA, Teixeira CE, Lorenzetti R, Okuyama CE, Antunes E, De Nucci G. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol 2008; 591(1-3): 189-95.
[http://dx.doi.org/10.1016/j.ejphar.2008.06.055] [PMID: 18593576]
[http://dx.doi.org/10.1016/j.ejphar.2008.06.055] [PMID: 18593576]
[28]
Glina S, Toscano I, Gomatzky C, de Góes PM, Júnior AN, Claro JF de A, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med 2009; 6: 553-7.http://www.ncbi.nlm.nih.gov/pubmed/19040623
[29]
Glina S, Fonseca GN, Bertero EB, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med 2010; 7(5): 1928-36.
[http://dx.doi.org/10.1111/j.1743-6109.2010.01711.x] [PMID: 20214718]
[http://dx.doi.org/10.1111/j.1743-6109.2010.01711.x] [PMID: 20214718]
[30]
Park HJ, Moon KH, Lee SW, Lee WK, Kam SC, Lee JH, et al. Mirodenafil for the Treatment of Erectile Dysfunction: A Systematic Review of the Literature. World J Mens Health 2014; 32: 18.http://www.ncbi.nlm.nih.gov/pubmed/24872948
[http://dx.doi.org/10.5534/wjmh.2014.32.1.18]
[http://dx.doi.org/10.5534/wjmh.2014.32.1.18]
[31]
De Nunzio C, Lombardo R, Tema G, Tubaro A. Erectile dysfunction and lower urinary tract symptoms. Curr Urol Rep 2018; 61.http://www.ncbi.nlm.nih.gov/pubmed/29858709
[32]
Philippou YA, Jung JH, Steggall MJ, O’driscoll ST, Bakker CJ, Bodie JA, et al. Penile rehabilitation for postprostatectomy erectile dysfunction. Cochrane Database Syst Rev 2018; CDO12414. http://www.ncbi.nlm.nih.gov/ pubmed/30352488
Article Metrics
16